Empowered Patient Podcast

Alexandra Paul is the Vice President of Strategic Partnerships at Accolade and Transcarent, a company that provides comprehensive healthcare for its members by integrating digital health solutions and leveraging AI. The company focuses on addressing the healthcare needs of underserved communities, such as truck drivers, and provides 24/7/365 access to virtual care. The Experience Store and WayFinding navigator utilizes AI and large language models to deliver real-time, chat-based guidance and personalized treatment options based on plan benefits.

Alexandra explains, "What's really important for us is ensuring that we are targeting the right buyer who can help us really get in front of members to help them navigate a complex healthcare experience. Our core foundation is being the one place to go for health and care. And so, whether that's through a health plan offering or whether that's through an employer benefit offering, we've truly become kind of that front door experience and what we call WayFinding, which is our AI-powered solution to help members get the right care."

"We're very excited about the Experience Store that we just launched, and a big part of that is making sure that we tap into technology. So, as we think about how we can provide this comprehensive care experience and this one place to go for health and care for members, we have been heavily focused on investing in AI and technology systems that make this care experience easier. A lot of that is really just thinking about large language models. So, members in their chat function can type in a question that AI in the new world, which feels so much like a person, can answer and provide real-time guidance to that member."

#Accolade #Transcarent #DigitalHealth #HealthcareBenefits #Healthcare #PersonalizedCare #HealthTech

accolade.com

transcarent.com

Listen to the podcast here

Alexandra Paul is the Vice President of Strategic Partnerships at Accolade and Transcarent, a company that provides comprehensive healthcare for its members by integrating digital health solutions and leveraging AI. The company focuses on addressing the healthcare needs of underserved communities, such as truck drivers, and provides 24/7/365 access to virtual care. The Experience Store and WayFinding navigator utilizes AI and large language models to deliver real-time, chat-based guidance and personalized treatment options based on plan benefits.

Alexandra explains, "What's really important for us is ensuring that we are targeting the right buyer who can help us really get in front of members to help them navigate a complex healthcare experience. Our core foundation is being the one place to go for health and care. And so, whether that's through a health plan offering or whether that's through an employer benefit offering, we've truly become kind of that front door experience and what we call WayFinding, which is our AI-powered solution to help members get the right care."

"We're very excited about the Experience Store that we just launched, and a big part of that is making sure that we tap into technology. So, as we think about how we can provide this comprehensive care experience and this one place to go for health and care for members, we have been heavily focused on investing in AI and technology systems that make this care experience easier. A lot of that is really just thinking about large language models. So, members in their chat function can type in a question that AI in the new world, which feels so much like a person, can answer and provide real-time guidance to that member."

#Accolade #Transcarent #DigitalHealth #HealthcareBenefits #Healthcare #PersonalizedCare #HealthTech

accolade.com

transcarent.com

Download the transcript here

Julio Martinez-Clark, Co-Founder and CEO of Bioaccess, a Latin American MedTech CRO that works with US-based medtech and biopharma startups to conduct their first-in-human trials outside the US to accelerate development and recruitment. Data from overseas clinical trials conducted to international standards is considered valid and can support conversations with investors, strategic partners, and the FDA. Drawing on resources in the Balkans, Latin America, and Australia, clinical trials can get faster approvals, more easily recruit patients, and benefit those living in the communities where clinical trials are conducted.

Julio explains, "The mission is to accelerate global clinical trials, and the type of clients is mostly us. Occasionally, we have European clients, but they're mostly San Francisco-based, Boston-based, San Diego-based, Minnesota-based, or Boston-based companies that are looking to execute a first-in-human clinical study outside of the United States. And for many reasons, Latin America is an obvious choice, at least for the exploratory phase. When they're looking for different countries, they usually explore Eastern Europe, Australia, and Latin America. And we help these companies, which have been predominantly US-based MedTech startups. More recently, we have expanded to biopharma as well. But let's talk with the conversation on MedTech startups, and their struggle to conduct these first inhuman trials in the United States. They seek help when they want to go overseas, and they call for us to help them find investigators and to recruit patients and to get past approvals, etc."

"There is one single thing, which is that these companies are startups. Getting this type of trial approved is really, really difficult and expensive. And the timeline to get them approved is really uncertain. So when you have a startup that has investors backing the company and they have a business plan, they have some milestones, it is difficult to predict when you're going to hit these milestones, and you need to keep the investors happy. So if you don't have a solid business plan, then you are not going to be able to raise more funds to continue your operation and development."

#BioAccess #GlobalTrialAccelerators #DigitalHealth #PrecisionMedicine #LATAMTrials #BalkansClinicalResearch #AustraliaCTN #AANVISA #ALIMS #MINSA #TrialAcceleration #FirstinHumanTrials #ClinicalTrials #MedTechInnovation #Biopharma #MedTech #PatientRecruitment #CRO

bioaccessla.com

Listen to the podcast here

Julio Martinez-Clark, Co-Founder and CEO of Bioaccess, a Latin American MedTech CRO that works with US-based medtech and biopharma startups to conduct their first-in-human trials outside the US to accelerate development and recruitment. Data from overseas clinical trials conducted to international standards is considered valid and can support conversations with investors, strategic partners, and the FDA. Drawing on resources in the Balkans, Latin America, and Australia, clinical trials can get faster approvals, more easily recruit patients, and benefit those living in the communities where clinical trials are conducted.

Julio explains, "The mission is to accelerate global clinical trials, and the type of clients is mostly us. Occasionally, we have European clients, but they're mostly San Francisco-based, Boston-based, San Diego-based, Minnesota-based, or Boston-based companies that are looking to execute a first-in-human clinical study outside of the United States. And for many reasons, Latin America is an obvious choice, at least for the exploratory phase. When they're looking for different countries, they usually explore Eastern Europe, Australia, and Latin America. And we help these companies, which have been predominantly US-based MedTech startups. More recently, we have expanded to biopharma as well. But let's talk with the conversation on MedTech startups, and their struggle to conduct these first inhuman trials in the United States. They seek help when they want to go overseas, and they call for us to help them find investigators and to recruit patients and to get past approvals, etc."

"There is one single thing, which is that these companies are startups. Getting this type of trial approved is really, really difficult and expensive. And the timeline to get them approved is really uncertain. So when you have a startup that has investors backing the company and they have a business plan, they have some milestones, it is difficult to predict when you're going to hit these milestones, and you need to keep the investors happy. So if you don't have a solid business plan, then you are not going to be able to raise more funds to continue your operation and development."

#BioAccess #GlobalTrialAccelerators #DigitalHealth #PrecisionMedicine #LATAMTrials #BalkansClinicalResearch #AustraliaCTN #AANVISA #ALIMS #MINSA #TrialAcceleration #FirstinHumanTrials #ClinicalTrials #MedTechInnovation #Biopharma #MedTech #PatientRecruitment #CRO

bioaccessla.com

Download the transcript here

Nicole Clark, Co-Founder and CEO of the Adult and Pediatric Institute for Health and Wellness, a comprehensive, personalized psychiatric practice that takes a holistic approach to mental health, looking at the interconnection of physical, cognitive, and emotional health. Nicole has two daughters with autism, which has informed the Institute's focus on serving the autism community, especially in these times of changes in the definition of autism spectrum disorder. Services include psychiatric and autism evaluations, medication management, education, and early intervention for children and adults and their family members.

Nicole explains, "We're a comprehensive psychiatric practice, and we're kind of unique in that we have fully blended behavioral and mental health therapy. We see an individual as a whole person. They're not just one piece of their identity. They have multiple pieces of their identity. And so we don't like to only focus on a singular issue. We like to look at the person as a whole, and so we see the entire family. We see ages 18 months when we're doing autism evaluations, all the way up to 65 years old. And we offer psychiatric evaluations, autism evaluations, medication management, and different therapy modalities."

"A lot of the time, we are treating someone's anxiety, or maybe we're treating their ADHD, or maybe we're treating bipolar depression, the other illnesses that are kind of stemming from that stomachache, especially with kids, the headaches, the 'I'm always feeling sick." I don't want to go to school."

"Or in adults-- the chronic stomachaches, the heart disease, all of these issues tend to start to resolve when you can treat the mind and when you can work on the mental health side of things, because these are real problems and these are real issues, physiological issues, heart disease. A heart attack, that's real. We know that is real. Well, what is causing that? Well, maybe it's being caused by elevated cortisol levels over an extended period of time because you have unresolved trauma, anxiety, or depression. And so, it's becoming a more collaborative approach to healthcare, which I love."

#PEDSInstitute #PsychiatricCare #MentalHealth #PediatricHealth #Autism #AutismDiagnosis #AutismAwareness

pedsinstitute.com

Listen to the podcast here

Nicole Clark, Co-Founder and CEO of the Adult and Pediatric Institute for Health and Wellness, a comprehensive, personalized psychiatric practice that takes a holistic approach to mental health, looking at the interconnection of physical, cognitive, and emotional health. Nicole has two daughters with autism, which has informed the Institute's focus on serving the autism community, especially in these times of changes in the definition of autism spectrum disorder. Services include psychiatric and autism evaluations, medication management, education, and early intervention for children and adults and their family members.

Nicole explains, "We're a comprehensive psychiatric practice, and we're kind of unique in that we have fully blended behavioral and mental health therapy. We see an individual as a whole person. They're not just one piece of their identity. They have multiple pieces of their identity. And so we don't like to only focus on a singular issue. We like to look at the person as a whole, and so we see the entire family. We see ages 18 months when we're doing autism evaluations, all the way up to 65 years old. And we offer psychiatric evaluations, autism evaluations, medication management, and different therapy modalities."

"A lot of the time, we are treating someone's anxiety, or maybe we're treating their ADHD, or maybe we're treating bipolar depression, the other illnesses that are kind of stemming from that stomachache, especially with kids, the headaches, the 'I'm always feeling sick." I don't want to go to school."

"Or in adults-- the chronic stomachaches, the heart disease, all of these issues tend to start to resolve when you can treat the mind and when you can work on the mental health side of things, because these are real problems and these are real issues, physiological issues, heart disease. A heart attack, that's real. We know that is real. Well, what is causing that? Well, maybe it's being caused by elevated cortisol levels over an extended period of time because you have unresolved trauma, anxiety, or depression. And so, it's becoming a more collaborative approach to healthcare, which I love."

#PEDSInstitute #PsychiatricCare #MentalHealth #PediatricHealth #Autism #AutismDiagnosis #AutismAwareness

pedsinstitute.com

Download the transcript here

Bob Roda, President and CEO of HemoSonics, highlights the current blood shortage and the challenges of patient blood management to minimize the need for transfusions. The HemoSonics Quanta Analyzer technology utilizes ultrasound to measure blood viscosity, providing real-time information on the patient's coagulation status and enabling clinicians to make more informed decisions about blood product administration. This approach can be applied in the operating room, emergency rooms, and hospital laboratories to improve patient outcomes and yield cost savings for the healthcare system.

Bob explains, "As a company, we are very centered and focused on helping to shape human healthcare moving forward. Specifically, as it relates to coagulation management, we have a technology that is about five years old, and in layman's terms, it helps to identify what is going on with your blood in terms of coagulation, intraoperatively, and in near real-time. So what does that mean? It means that it is an aid for clinicians as they're making determinations for their patients as to what to do next in terms of managing their bleeding situations."

"Think about patient blood management as a patient-centered, systematic, and evidence-based approach to improving patient outcomes simply by managing and preserving a patient's own blood while promoting safety and ultimately the empowerment of the patient. So what does that mean? What it means is that there is a multifaceted approach in terms of any surgical intervention, where ultimately your own blood, the patient's own blood, is really what's best for them. And so to the extent that you can limit or prevent or get ahead of the need for transfusion, that's ultimately to the benefit of the patient and to the benefit of the healthcare system from an economic perspective."

#HemoSonics #Hemostasis #BloodManagement #Quantra #BleedingManagement #MedTech #HealthcareInnovation

hemosonics.com

Listen to the podcast here

Bob Roda, President and CEO of HemoSonics, highlights the current blood shortage and the challenges of patient blood management to minimize the need for transfusions. The HemoSonics Quanta Analyzer technology utilizes ultrasound to measure blood viscosity, providing real-time information on the patient's coagulation status and enabling clinicians to make more informed decisions about blood product administration. This approach can be applied in the operating room, emergency rooms, and hospital laboratories to improve patient outcomes and yield cost savings for the healthcare system.

Bob explains, "As a company, we are very centered and focused on helping to shape human healthcare moving forward. Specifically, as it relates to coagulation management, we have a technology that is about five years old, and in layman's terms, it helps to identify what is going on with your blood in terms of coagulation, intraoperatively, and in near real-time. So what does that mean? It means that it is an aid for clinicians as they're making determinations for their patients as to what to do next in terms of managing their bleeding situations."

"Think about patient blood management as a patient-centered, systematic, and evidence-based approach to improving patient outcomes simply by managing and preserving a patient's own blood while promoting safety and ultimately the empowerment of the patient. So what does that mean? What it means is that there is a multifaceted approach in terms of any surgical intervention, where ultimately your own blood, the patient's own blood, is really what's best for them. And so to the extent that you can limit or prevent or get ahead of the need for transfusion, that's ultimately to the benefit of the patient and to the benefit of the healthcare system from an economic perspective."

#HemoSonics #Hemostasis #BloodManagement #Quantra #BleedingManagement #MedTech #HealthcareInnovation

hemosonics.com

Download the transcript here

Dr. David Carmouche, Chief Clinical Transformation Officer at Lumeris, is addressing the primary care shortage by providing a platform that supports primary care physicians in managing a broader patient population and delivering better health outcomes. The Lumeris platform, Tom, is an AI-powered virtual assistant that can interact with patients, provide chronic disease management, education and support, and coordinate care on behalf of providers. Tom can improve efficiency, reduce clinician burnout, and provide more convenient and personalized experiences for patients.

David explains, "And so, they built the company, Lumeris, as a commercialization arm of their relationship to empower other primary care physicians to manage populations and deliver better health outcomes at a lower cost. And so for the last 12 years or so, Lumaris has been partnering largely with large medical groups and health systems to help them manage populations, Medicare, Medicaid, and commercial populations, and helping drive high performance and high outcomes within those relationships. The economics are shared economics, so when the plans and providers are successful by delivering better outcomes, Lumeris shares in those rewards."

"Given the 20-year history that I mentioned of understanding care deeply as a provider of care and as a partner to those providers of care, we have the fortune to build new technology to support primary care. Our environment starts with aggregating data, and that data helps us define a view of a patient. That data could come from an electronic medical record, it could come from claims data from a pharmacist, it could come from claims data from a payer, or it could come from a pharmacist or a lab. It could be consumer data that is purchasable, as organizations like Target, Walmart, and others use to market to us today. We aggregate that data to create a 360° view of a patient. Then we're able to leverage some of the new artificial intelligence that creates the ability for the platform to interact with patients on behalf of their clinical care teams at points in time where we understand that there is a defined next best clinical action that might help you in your health journey."

#Lumeris #MedAI #DigitalHealth #PrimaryCareProviders

lumeris.com

Listen to the podcast here

Dr. David Carmouche, Chief Clinical Transformation Officer at Lumeris, is addressing the primary care shortage by providing a platform that supports primary care physicians in managing a broader patient population and delivering better health outcomes. The Lumeris platform, Tom, is an AI-powered virtual assistant that can interact with patients, provide chronic disease management, education and support, and coordinate care on behalf of providers. Tom can improve efficiency, reduce clinician burnout, and provide more convenient and personalized experiences for patients.

David explains, "And so, they built the company, Lumeris, as a commercialization arm of their relationship to empower other primary care physicians to manage populations and deliver better health outcomes at a lower cost. And so for the last 12 years or so, Lumaris has been partnering largely with large medical groups and health systems to help them manage populations, Medicare, Medicaid, and commercial populations, and helping drive high performance and high outcomes within those relationships. The economics are shared economics, so when the plans and providers are successful by delivering better outcomes, Lumeris shares in those rewards."

"Given the 20-year history that I mentioned of understanding care deeply as a provider of care and as a partner to those providers of care, we have the fortune to build new technology to support primary care. Our environment starts with aggregating data, and that data helps us define a view of a patient. That data could come from an electronic medical record, it could come from claims data from a pharmacist, it could come from claims data from a payer, or it could come from a pharmacist or a lab. It could be consumer data that is purchasable, as organizations like Target, Walmart, and others use to market to us today. We aggregate that data to create a 360° view of a patient. Then we're able to leverage some of the new artificial intelligence that creates the ability for the platform to interact with patients on behalf of their clinical care teams at points in time where we understand that there is a defined next best clinical action that might help you in your health journey."

#Lumeris #MedAI #DigitalHealth #PrimaryCareProviders

lumeris.com

Download the transcript here